Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Metabolic Health: Why We Go Beyond A1C
Fishtown Medicine•15 min read

Metabolic Health: Why We Go Beyond A1C

A 'normal' A1C isn't the whole story. Catching compensated insulin resistance early through fasting insulin, HOMA-IR, and red-cell context.

On This Page
  • Table of Contents
  • What do fasting glucose, HbA1c, fasting insulin, HOMA-IR, and TG/HDL-C each measure?
  • How many years before diabetes does insulin resistance begin?
  • Does fasting insulin or HOMA-IR beat glucose and HbA1c at predicting diabetes or heart events?
  • What is a healthy fasting insulin level, and why do lab assays vary?
  • Why you should always compare fasting insulin on the same lab platform (Marcovina 2007; Rohlfing 2025)
  • When does HbA1c give a false reading?
  • What does a very low fasting insulin (under 3 uIU/mL) mean?
  • Guidelines from the Clinic
  • Actionable Steps for Metabolic Reset
  • Common Questions
  • What fasting insulin range does Fishtown Medicine aim for?
  • Why does Fishtown Medicine test fasting insulin when HbA1c is normal?
  • Why does Fishtown Medicine set a lower floor of 3 uIU/mL on fasting insulin?
  • What is HOMA-IR, and why do HOMA1 and HOMA2 give different numbers?
  • Can HbA1c be falsely high or falsely low when blood sugar is normal?
  • Should I get a CGM if I do not have diabetes?
  • Deep Questions
  • What did the Whitehall II and IRAS studies prove about the timeline to diabetes?
  • Why don't standard guidelines recommend universal fasting insulin screening (Sacks et al., Diabetes Care 2023)?
  • When does the triglyceride-to-HDL (TG/HDL-C) ratio mislead?
  • Why can a low HOMA-IR be dangerous if fasting glucose is high?
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

HbA1c and fasting glucose measure blood sugar, whereas fasting insulin, HOMA-IR, and TG/HDL-C show how hard your pancreas is working to keep that sugar normal. In longitudinal cohorts (Whitehall II, n = 6,538; IRAS), lower insulin sensitivity (-34.2 HOMA2-%S points) and higher compensatory insulin secretion (+34% acute insulin response) appear 5 to 13 years before beta-cell decompensation drives blood sugar into diabetes. At the same time, HbA1c is skewed by red blood cell lifespan (38 to 60 days even in healthy adults, iron/B12 deficiency, hemolysis, or sickle cell trait [-0.29%]), and commercial insulin assays vary by 12% to 66% across labs (Rohlfing 2025). Fishtown Medicine pairs glycemic screening with same-platform fasting insulin (aiming for 3 to 6 uIU/mL while evaluating <3 uIU/mL for endurance adaptation vs RED-S under-fueling), HOMA-IR, and TG/HDL-C.

TL;DR: A normal HbA1c (< 5.7%) and fasting glucose (< 100 mg/dL) tell you that your blood sugar is still controlled today. They do not tell you how much extra insulin your pancreas is pumping to hold that line:

  1. Early physiological detection vs. late glycemic rise (Whitehall II & IRAS): In the Whitehall II cohort (Tabák et al., Lancet 2009, n = 6,538), adults who later developed type 2 diabetes already had 34.2 percentage points lower insulin sensitivity (HOMA2-%S) and higher compensatory insulin secretion (HOMA2-%B 85.0% vs 74.6%) 5 to 13 years before diagnosis. That long compensation was followed by a sharp 3-year beta-cell drop (HOMA2-%B down to 62.4%) as fasting glucose jumped from 104 to 133 mg/dL. In IRAS (Festa et al., Diabetes 2006), adults kept glucose normal over 5.2 years only by boosting acute insulin secretion +34% to offset a -35% drop in insulin sensitivity.
  2. Complementary physiology alongside standard screening (Hoorn, PROSPER, ADA 2023/2026): Because diabetes is defined by blood sugar, baseline fasting glucose (OR 9.0 in the Hoorn Study) and HbA1c (OR 3.8) remain stronger direct predictors of crossing the diabetes line than HOMA-IR (OR 2.8) or fasting insulin alone (OR 1.9). We add fasting insulin, HOMA-IR, and TG/HDL-C to catch compensated metabolic strain early, alongside standard glycemic and heart screening (ApoB, blood pressure, hs-CRP).
  3. Why our 3 to 6 uIU/mL insulin window is tracked on the same lab (Rohlfing 2025): Commercial lab reference ranges run up to 25 uIU/mL, while healthy non-obese cohorts average 5.1 to 5.8 uIU/mL. Because commercial insulin immunoassays vary by 12% to 66% across manufacturers (only 1 of 12 assays matched mass spectrometry in Rohlfing et al., CCLM 2025), we use 3 to 6 uIU/mL (6.1 to 9.0 borderline, 9.1+ high) as a clinical range tracked serially on the same lab platform.
  4. When HbA1c misleads (Cohen Blood 2008, Lacy JAMA 2017) and when low insulin (< 3 uIU/mL) warns of under-fueling (IOC REDs 2023): Mean red blood cell (RBC) age ranges from 38 to 60 days even in healthy adults, and iron/B12 deficiency, hemolysis, or sickle cell trait (-0.29% lower HbA1c) can skew HbA1c. Meanwhile, a fasting insulin below 3 uIU/mL requires clinical context to separate healthy endurance training sensitivity from low energy availability (RED-S, which cuts insulin by 34% to 38%) or failing beta-cell secretion.
Three-column clinical diagram of Metabolic Health Beyond HbA1c: Column 1 shows the Whitehall II and IRAS timeline (5 to 13 years of lower HOMA2-%S sensitivity [-34.2 pts] and compensatory secretion [HOMA2-%B 85% vs 75%, IRAS +34% AIR] before final 3-year beta-cell decompensation [FPG 104 to 133 mg/dL]); Column 2 shows Fishtown Medicine's 3 to 6 uIU/mL fasting insulin range vs 25 uIU/mL commercial lab ceiling, the <3 uIU/mL context gate (endurance adaptation vs RED-S under-fueling), and same-platform assay tracking (12-66% inter-lab CV); Column 3 shows HbA1c red-cell lifespan confounders (falsely high in iron/B12 deficiency, falsely low in hemolysis or sickle cell trait [-0.29%]) and TG/HDL-C caveats.
How compensated insulin resistance precedes glycemic failure, how we interpret the 3 to 6 uIU/mL fasting insulin window on a consistent lab platform, and when red blood cell turnover skews HbA1c.

Table of Contents

  • What do fasting glucose, HbA1c, fasting insulin, HOMA-IR, and TG/HDL-C each measure?
  • How many years before diabetes does insulin resistance begin?
  • Does fasting insulin or HOMA-IR beat glucose and HbA1c at predicting diabetes or heart events?
  • What is a healthy fasting insulin level, and why do lab assays vary?
  • When does HbA1c give a false reading?
  • What does a very low fasting insulin (under 3 uIU/mL) mean?
  • Guidelines from the Clinic
  • Actionable Steps for Metabolic Reset
  • Common Questions
  • Deep Questions

What do fasting glucose, HbA1c, fasting insulin, HOMA-IR, and TG/HDL-C each measure?

Fasting glucose (FPG) and HbA1c measure blood sugar concentration, whereas fasting insulin, HOMA-IR, and the triglyceride-to-HDL (TG/HDL-C) ratio measure the hormonal effort and lipid spillover behind that blood sugar.123

Many patients are told their metabolism is healthy because their HbA1c is under 5.7% and their fasting glucose is under 100 mg/dL (the American Diabetes Association prediabetes cutoffs).45 Those numbers matter, yet each test captures a different piece of physiology:

  • Fasting Plasma Glucose (FPG) & HbA1c: Measure circulating glucose (FPG) and the percentage of hemoglobin coated with sugar over the life of your red blood cells (HbA1c). Normal blood sugar can coexist with significant insulin resistance as long as your pancreatic beta cells pump extra insulin to compensate.67 Conversely, weak beta-cell secretion can let blood sugar drift up without high insulin.7
  • Fasting Insulin: Reflects three things at once: basal pancreatic insulin secretion, liver (hepatic) extraction (50% to 80% of portal insulin is cleared on first pass), and whole-body clearance.89 In a gold-standard hyperinsulinemic-euglycemic clamp study of obese men (ter Horst et al., Int J Obes 2015), fasting insulin detected peripheral insulin resistance with an AUC of ~0.80 compared to 0.55 for fasting glucose.10 Across broader cohorts (Otten et al., Diabetologia 2014 meta-analysis), fasting surrogates correlate moderately with clamp sensitivity (r ~ 0.60 to 0.65).1112
  • HOMA-IR (HOMA1 vs HOMA2): Pairs fasting insulin and fasting glucose to model basal liver-pancreas feedback. Classic HOMA1-IR is calculated as (fasting insulin [uIU/mL] x fasting glucose [mg/dL]) / 405, whereas HOMA2-IR uses a non-linear computer model. The two scores are not numerically interchangeable (an upper 95th percentile of 2.68 on HOMA1-IR corresponds to 1.80 on HOMA2-IR in the same healthy cohort, Tohidi et al., Clin Biochem 2014).1314
  • Triglyceride-to-HDL-C (TG/HDL-C) Ratio: Captures liver VLDL triglyceride export and CETP-driven HDL remodeling when liver insulin signaling is strained.1516 Two rules apply: (1) you must use mg/dL units (because mmol/L conversion factors differ between triglycerides and cholesterol), and (2) TG/HDL-C can underestimate insulin resistance in adults of African ancestry, where lipoprotein lipase activity often keeps triglycerides low despite insulin resistance (Kim-Dorner et al., Metabolism 2010).1517

How many years before diabetes does insulin resistance begin?

Compensated insulin resistance and hypersecretion are detectable 5 to 13 years before a type 2 diabetes diagnosis, with rapid beta-cell decompensation typically occurring in the final 3 to 5 years (moderate-to-high certainty).126

Three landmark prospective cohorts map how the pancreas compensates before blood sugar breaks through diagnostic cutoffs:

Cohort & Study DesignSample Size & Follow-UpPhysiological Trajectory & Effect SizesKey Clinical Nuance & Limitations
Whitehall II (Tabák et al., Lancet 2009)6,538 adults (505 incident T2D cases, 7.7%) over median 9.7 yrs (modeled 13 yrs back)Years -13 to -5: Future cases already had -34.2 percentage points lower HOMA2-%S sensitivity and higher HOMA2-%B secretion (85.0% vs 74.6%). Years -4 to -3: HOMA2-%B rose to 92.6%. Final 3 years: HOMA2-%B fell to 62.4% as FPG jumped from 104 to 133 mg/dL (5.79 to 7.40 mmol/L).1Modeled FPG in future cases was already ~98 mg/dL at -13 yrs and 104 mg/dL at -3 yrs, so Whitehall II shows a decade-plus lag before diabetes diagnosis, not that every patient kept FPG < 100 and HbA1c < 5.7% for 13 years.11819
IRAS (Festa et al., Diabetes 2006; Lorenzo et al., Diabetes Care 2010)826 multiethnic adults (128 incident T2D, 15.5%) over 5 to 5.2 yrs with repeat FSIGTParticipants who kept normal glucose tolerance over 5.2 years had a -35% drop in insulin sensitivity ($S_I$) that was offset by a +34% jump in acute insulin response (AIR). Each 1-SD higher $S_I$ (OR 0.50) and AIR (OR 0.51) cut 5-year diabetes risk in half.26Direct repeat intravenous testing proves that rising insulin secretion masks falling sensitivity until beta cells tire out.2620
San Antonio Heart Study (Haffner et al., Diabetes 1992 & Diabetologia 1996/1997)1,276 Mexican-American (11.7% T2D) & non-Hispanic White (5.0% T2D) adults over 7 to 8 yrsIn adults starting with normal glucose tolerance, 17.6% (148/839) progressed to impaired glucose tolerance (IGT) over 7 years. High baseline fasting insulin and blunted 30-minute insulin response independently predicted conversion.212223Establishes a 7-to-8-year predictive signal across diverse ancestries, adjusted for body mass index.2122

Does fasting insulin or HOMA-IR beat glucose and HbA1c at predicting diabetes or heart events?

No - earlier physiological detection is not the same as superior standalone outcome prediction (moderate certainty for diabetes; low-to-moderate certainty for incremental heart risk).32425

Because clinical diabetes is defined by blood glucose and HbA1c thresholds, a patient whose fasting glucose (98 mg/dL) or HbA1c (5.6%) is already close to the diagnostic line is statistically nearer to crossing that line than someone with high insulin and a fasting glucose of 82 mg/dL:

  • Incident Type 2 Diabetes (Hoorn, PROSPER, Panasonic Cohort):
    • In the population-based Hoorn Study (Ruijgrok et al., Diabetologia 2018, n = 1,349, 11.3% incident T2D over 6.4 years), top-versus-bottom quintile adjusted odds ratios were 9.0 (95% CI 4.4 to 18.5) for FPG, 6.1 (2.9 to 12.7) for 2-hour post-load glucose, 3.8 (2.0 to 7.2) for HbA1c, 2.8 (1.4 to 5.6) for HOMA-IR, and 1.9 (0.9 to 3.6) for fasting insulin.3
    • In older adults (70 to 82 years) in PROSPER (Welsh et al., Diabetologia 2014, n = 4,742, 6.0% incident T2D over 3.2 years), top-versus-bottom tertile HOMA-IR (HR 4.80, 95% CI 3.14 to 7.33) and fasting insulin (HR 2.43, 1.65 to 3.58) strongly predicted diabetes.26
    • In the Panasonic Cohort Study 10 (Yuge et al., Cardiovasc Diabetol 2023, n = 120,613, 5.0% incident T2D over 6 years), TG/HDL-C independently predicted diabetes (HR 1.03 per unit after adjusting for FPG; 10-year AUC 0.679).17
  • Cardiovascular Events (Gast Meta-Analysis, SAHS, Chen Meta-Analysis vs PROSPER):
    • Across 65 studies (516,325 adults without diabetes, Gast et al., PLoS One 2012), each 1-SD rise in HOMA-IR was linked to a 46% higher coronary heart disease risk (RR 1.46, 95% CI 1.26 to 1.69), compared with RR 1.21 (1.13 to 1.30) for fasting glucose and RR 1.04 (0.96 to 1.12) for fasting insulin alone.24
    • In the San Antonio Heart Study (Hanley et al., Diabetes Care 2002, n = 2,569, 7.3% CVD events over 8 years), top-quintile HOMA-IR carried an adjusted OR of 1.94 (1.05 to 3.59).27 Across 13 cohorts (207,515 adults, Chen et al., NMCD 2022), high TG/HDL-C carried HR 1.43 (1.26 to 1.62; 1.26 after publication-bias adjustment).28
    • However, in older high-risk adults in PROSPER (Welsh et al., 2014) and in normoglycemic adults in a large Chinese cohort (Wang et al., Diabetes Care 2022), HOMA-IR did not add heart prediction (HR 0.94 and HR 1.03) once standard risk factors were included.2629
  • What this means for your panel (ADA / AACC 2023 Guideline, Sacks et al.): Fasting insulin, HOMA-IR, and TG/HDL-C complement and never replace HbA1c, fasting glucose, ApoB, and blood pressure.2530 We use them to spot compensated insulin resistance early so you can adjust nutrition, muscle mass, and sleep before blood sugar ever rises.

What is a healthy fasting insulin level, and why do lab assays vary?

In healthy, lean, non-diabetic cohorts, median fasting insulin is 5.1 to 5.8 uIU/mL (well below commercial lab ceilings of 18 to 25 uIU/mL), which is why Fishtown Medicine uses 3 to 6 uIU/mL as our optimal preventive range while tracking results on the same lab platform (high certainty on inter-assay variability).133132

Study / Cohort & Assay PlatformSample & Reference PopulationFasting Insulin & HOMA-IR DistributionClinical Takeaway
Commercial Lab Interval (Xu et al., Anal Biochem 2020, ADVIA Centaur XP)Routine clinical laboratory reference population3.0 to 25.0 uIU/mL (mIU/L)Reflects an unselected population with high rates of overweight and silent insulin resistance.33
D.E.S.I.R. Cohort (Gallois et al., Diabetes Metab 1996, Abbott EIA)3,081 non-diabetic reference adults (from n = 4,032)Medians 5.1 to 5.6 uIU/mL (95th percentiles 11.2 to 12.6 uIU/mL)Typical values in metabolically healthy adults cluster between 3 and 6 uIU/mL.31
Tehran Lipid & Glucose Study (Tohidi et al., 2014 & Ghasemi et al., 2015, ECLIA)309 healthy non-obese adults (4,942 followed 9.2 yrs for T2D, 7.0% incidence)Central 95% insulin: 2.11 to 12.49 uIU/mL. HOMA1-IR: 0.63 to 2.68 vs HOMA2-IR: 0.40 to 1.80. ROC T2D cutoffs: 9.16 (men) / 11.13 (women)Shows why HOMA1 and HOMA2 cannot be mixed, and why risk rises sharply above ~9 uIU/mL.1334
Healthy Reference Cohorts (Li et al., 2012; Matli et al., CCLM 2021)1,434 healthy men (Li); 1,065 stringent healthy adults (Matli)Median insulin 5.79 uIU/mL (1.57 to 16.32); median HOMA-IR 1.09 (IQR 0.85 to 1.42, 97.5th 2.35)Confirms that healthy HOMA-IR centers near ~1.0 (IQR < 1.5).3536

Why you should always compare fasting insulin on the same lab platform (Marcovina 2007; Rohlfing 2025)

Unlike HbA1c (which is standardized globally by the NGSP), commercial serum insulin immunoassays are not yet fully standardized:

  • An American Diabetes Association (ADA) Workgroup (Marcovina et al., Clin Chem 2007) found between-laboratory coefficients of variation (CV) of 12% to 66% (median 24%) across commercial insulin assays.37
  • In 2025, Rohlfing et al. (Clin Chem Lab Med 2025) compared 12 current insulin assays from 9 manufacturers against the gold-standard isotope-dilution mass spectrometry (IDMS) reference method: only 1 of 12 assays fully met agreement criteria, even though each individual lab platform had tight internal repeatability.32
  • Our clinical rule: Our 3 to 6 uIU/mL optimal window (6.1 to 9.0 uIU/mL borderline high; 9.1+ uIU/mL high) is a preventive heuristic read alongside fasting glucose, HbA1c, TG/HDL-C, ALT/GGT, and waist circumference. We track your serial draws on the same laboratory platform (Quest or LabCorp) under standardized 10-to-12-hour morning fasting conditions.

When does HbA1c give a false reading?

Even when your lab test is accurate, variations in average red blood cell (RBC) age (38 to 60 days in healthy adults, Cohen et al., Blood 2008) or hemoglobin variants (-0.29% in sickle cell trait, Lacy et al., JAMA 2017) can push HbA1c falsely high or falsely low at the same blood sugar (high certainty).383940

In a biotin-labeling study (Cohen et al., Blood 2008), mean circulating RBC age ranged from 38 to 60 days even among healthy non-diabetic adults. That spread is wide enough to shift HbA1c across diagnostic cutoffs without any change in blood sugar.38

Condition or ConfounderEffect on HbA1c at Identical Blood SugarBiological or Assay Mechanism & Clinical Action
Iron Deficiency & Iron-Deficiency Anemia (English et al., Diabetologia 2015; Cavagnolli 2015)Falsely Higher HbA1c (moderate certainty)Slower red cell turnover and altered glycation raise HbA1c into the "prediabetes" range (5.7% to 6.0%) despite normal glucose and insulin; recheck after iron repletion.414243
Vitamin B12 or Folate Deficiency (Gram-Hansen 1990)Often Higher HbA1c (low-moderate certainty)Reduced red cell production increases average age of circulating cells; B12/folate treatment drops HbA1c as young reticulocytes enter blood.4144
Splenectomy / Asplenia (O'Keeffe et al., JAMA 2016)Often Higher HbA1c (context-dependent)Slower clearance of aged red cells lengthens glycation exposure when underlying hemolysis is absent.45
Hemolysis or Blood Loss (Kiniwa 2019; Saudek JAMA 2006)Falsely Lower HbA1c (high certainty)Shortened red cell survival cuts glycation time regardless of assay method, hiding high blood sugar.4647
Sickle Cell Trait (HbAS) & Hemoglobin Variants (Lacy et al., JAMA 2017; Rohlfing 2016)Falsely Lower (-0.29% in HbAS) or Method-Dependent (high certainty)At the same fasting or 2-hour glucose, African American adults with sickle cell trait had 0.29 percentage points lower HbA1c (Lacy 2017).3940
Advanced Chronic Kidney Disease (KDIGO 2022; Galindo 2020)Often Lower / Bidirectional (high certainty that reliability drops)Shortened RBC survival, erythropoietin (ESA), or iron infusions skew HbA1c downward.4849

When HbA1c and fasting glucose disagree, we follow ADA 2026 Standards of Care (Bajaj et al., Diabetes Care 2025): we check a CBC with MCV/reticulocytes, ferritin, B12/MMA, and use plasma glucose criteria, oral glucose tolerance testing (OGTT), fructosamine / glycated albumin, or a 2-week preventive CGM.449

What does a very low fasting insulin (under 3 uIU/mL) mean?

An isolated fasting insulin below 3 uIU/mL is not an automatic badge of health and cannot by itself diagnose RED-S; interpreting it requires pairing the number with your training load, calorie intake, blood sugar, and hormone panel (low certainty for any standalone cutoff; high clinical utility as a context gate).85051

At Fishtown Medicine, we keep our optimal fasting insulin as a 3 to 6 uIU/mL range because readings of 1 or 2 uIU/mL branch into three distinct physiological states:

Clinical Context Accompanying < 3 uIU/mLUnderlying Physiology & Trial EvidenceNext Clinical Step at Fishtown Medicine
1. Well-fueled endurance athlete with stable weight, normal glucose, and healthy hormonesHigh insulin sensitivity & hepatic clearance (King et al., J Appl Physiol 1987; Engdahl et al., 1995): Endurance-trained adults show higher clamp glucose disposal with smaller pulsatile insulin bursts.5253Reassurance (no need to raise insulin). If energy, menstrual cycles or testosterone, bone density, and blood sugar are healthy, a low fasting insulin is normal adaptation.5052
2. High training volume or calorie restriction with fatigue, missed periods, low libido/T, or bone stress injuriesLow Energy Availability / RED-S (Koehler et al., J Sports Sci 2016; IOC REDs Consensus 2023, Mountjoy & Stellingwerff BJSM 2023): Just 4 days of low energy availability cuts fasting insulin by 34% to 38% alongside leptin.505154Never prescribe fasting or restriction. Run the multidimensional IOC REDs CAT2 evaluation: thyroid (TSH, free T4, free T3), morning sex hormones (LH, FSH, estradiol or total/free T), ferritin, and a DEXA scan with Z-scores, and restore carbohydrate/protein fueling around workouts.505155
3. Prolonged fasting (36-60 hrs) OR rising fasting glucose (>= 100 mg/dL) / high HbA1cFasting glucose-sparing adaptation (Jørgensen 2021) OR Beta-Cell Secretory Failure (Stone et al., Diabetes Care 2024): Low insulin with high blood sugar means the pancreas is failing to secrete insulin (LADA, monogenic, or pancreatogenic diabetes), making a low HOMA-IR falsely reassuring.45657Repeat after standardized 10-to-12-hour overnight fasting (if drawn after prolonged fasting). If glucose or HbA1c is high alongside low insulin, order paired fasting C-peptide + glucose and islet autoantibodies (GAD65, IA-2, ZnT8).457

Guidelines from the Clinic

Dr. Ash
"A normal HbA1c tells us your blood sugar hasn't broken through the dam yet, while fasting insulin and HOMA-IR tell us how much pressure is building behind the wall. In Whitehall II and IRAS, compensatory insulin changes showed up five to thirteen years before diabetes was diagnosed. At the same time, we respect what the evidence says about assay limits and red-cell biology: we track your fasting insulin on the same lab platform aiming for 3 to 6 uIU/mL, we check whether iron deficiency or red-cell turnover is skewing your A1C, and when insulin drops to 1 or 2 uIU/mL, we look at the whole athlete to separate healthy endurance fitness from under-fueling and RED-S."

Actionable Steps for Metabolic Reset

Move beyond a single 90-day average:

  1. Add Fasting Insulin, HOMA-IR, and TG/HDL-C (mg/dL) on the Same Lab Platform: Ask for a 10-to-12-hour morning fasting draw on a consistent lab (Quest or LabCorp) alongside fasting glucose and HbA1c so assay differences (12% to 66% across manufacturers) never cloud your trend.
  2. Audit HbA1c Discordance Against Your Red Blood Cells: If your HbA1c is 5.6% to 5.9% while your fasting insulin (3 to 5 uIU/mL) and fasting glucose (82 mg/dL) are ideal, check ferritin, B12/folate, MCV, or a 2-week preventive CGM before accepting a prediabetes label.
  3. Build Your Largest Glucose Sink (Skeletal Muscle): Progressive resistance training 2 to 4 days per week plus Zone 2 aerobic work increases muscle GLUT4 glucose disposal without requiring extra pancreatic insulin.
  4. Anchor Meals with Protein (30-40g) and Walk 10 Minutes After Eating: Eating protein and fiber first and taking a 10-minute post-meal walk blunts post-meal glucose excursions and reduces cumulative beta-cell secretory demand.
  5. Respect the < 3 uIU/mL Floor in Active Men and Women: If your fasting insulin is 1 or 2 uIU/mL and you feel fatigued, cold, injured, or hormonally flat, fuel with carbohydrates and protein around training instead of fasting.

Related at Fishtown Medicine

  • 9-System Biomarker Reference Guide: Optimal vs Standard Lab Ranges - complete reference for fasting insulin, HOMA-IR, TG/HDL, ApoB, liver enzymes, and all 9 systems
  • How to Read Your Lab Results - why reference intervals hide early metabolic drift and how to read your trend
  • Understanding Insulin Resistance - how muscle and liver insulin signaling work
  • Insulin Resistance at a Normal Weight - why body mass index misses lean visceral insulin resistance
  • Preventive CGM Guide - using 2-to-4-week continuous glucose monitoring to map personal food and sleep responses
  • ApoB & Heart Health - why insulin resistance creates discordance between normal LDL-C and high ApoB particle number
  • High Ferritin: From Iron Overload to Inflammation - why 90% of high ferritin is metabolic (MASLD / DIOS)
  • Autoimmune Gastritis & Low Ferritin - how iron deficiency falsely raises HbA1c
  • Body Composition Testing (DEXA) - quantifying visceral fat (VAT), skeletal muscle (ALMI), and bone Z-scores in RED-S

Scientific References

  1. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. "Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study." The Lancet. 2009;373(9682):2215-2221. PubMed
  2. Lorenzo C, Wagenknecht LE, D'Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM. "Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study." Diabetes Care. 2010;33(1):67-72. PubMed
  3. Ruijgrok C, Dekker JM, Beulens JW, et al. "Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study." Diabetologia. 2018;61(1):93-100. DOI
  4. Bajaj M, McCoy RG, Balapattabi K, et al.; American Diabetes Association Professional Practice Committee. "2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes - 2026." Diabetes Care. 2026;49(Suppl 1):S27-S49. DOI
  5. Kalyani RR, Neumiller JJ, Maruthur NM, Wexler DJ. "Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review." JAMA. 2025. DOI
  6. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. "The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study." Diabetes. 2006;55(4):1114-1120. PubMed
  7. Esser N, Utzschneider KM, Kahn SE. "Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia." Diabetologia. 2020;63(10):2007-2021. DOI
  8. Goodarzi MO, Cui J, Chen YD, Hsueh WA, Guo X, Rotter JI. "Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance." American Journal of Physiology-Endocrinology and Metabolism. 2011;301(2):E402-E408. PubMed
  9. Kim SH, Reaven GM. "Insulin clearance: an underappreciated modulator of plasma insulin concentration." Journal of Investigative Medicine. 2016;64(7):1162-1165. DOI
  10. ter Horst KW, Gilijamse PW, Koopman KE, et al. "Insulin resistance in obesity can be reliably identified from fasting plasma insulin." International Journal of Obesity. 2015;39(12):1703-1709. DOI
  11. Otten J, Ahrén B, Olsson T. "Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis." Diabetologia. 2014;57(9):1781-1788. DOI
  12. Abbasi F, Okeke Q, Reaven GM. "Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR)." Acta Diabetologica. 2014;51(2):193-197. PubMed
  13. Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. "Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study." Clinical Biochemistry. 2014;47(6):432-438. PubMed
  14. Haffner SM, Miettinen H, Stern MP. "The homeostasis model in the San Antonio Heart Study." Diabetes Care. 1997;20(7):1087-1092. PubMed
  15. Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M. "Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?" Metabolism. 2010;59(2):299-304. PubMed
  16. Yang Y, Wang B, Yuan H, Li X. "Triglycerides to High-Density Lipoprotein Cholesterol Ratio Is the Best Surrogate Marker for Insulin Resistance in Nonobese Middle-Aged and Elderly Population: A Cross-Sectional Study." International Journal of Endocrinology. 2021;2021:6676569. DOI
  17. Yuge H, Okada H, Hamaguchi M, et al. "Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10." Cardiovascular Diabetology. 2023;22(1):308. DOI
  18. Færch K, Witte DR, Tabák AG, et al. "Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study." The Lancet Diabetes & Endocrinology. 2013;1(1):43-51. PubMed
  19. Hulman A, Simmons RK, Brunner EJ, et al. "Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study." Diabetologia. 2017;60(7):1252-1260. DOI
  20. Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ. "Longitudinal decline of beta-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study." The Journal of Clinical Endocrinology & Metabolism. 2013;98(10):4152-4159. PubMed
  21. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. "Prospective analysis of the insulin-resistance syndrome (syndrome X)." Diabetes. 1992;41(6):715-722. PubMed
  22. Haffner SM, Miettinen H, Stern MP. "Are risk factors for conversion to NIDDM similar in high and low risk populations?" Diabetologia. 1997;40(1):62-69. PubMed
  23. Haffner SM, Miettinen H, Gaskill SP, Stern MP. "Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance." Diabetologia. 1996;39(10):1201-1207. PubMed
  24. Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. "Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis." PLoS One. 2012;7(12):e52036. PubMed
  25. Sacks DB, Arnold M, Bakris GL, et al. "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus." Diabetes Care. 2023;46(10):e151-e199. PubMed
  26. Welsh P, Preiss D, Lloyd SM, et al. "Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up." Diabetologia. 2014;57(12):2513-2523. DOI
  27. Hanley AJ, Williams K, Stern MP, Haffner SM. "Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study." Diabetes Care. 2002;25(7):1177-1184. PubMed
  28. Chen Y, Chang Z, Liu Y, et al. "Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies." Nutrition, Metabolism and Cardiovascular Diseases. 2022;32(2):318-329. PubMed
  29. Wang T, Li M, Zeng T, et al. "Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study." Diabetes Care. 2022;45(8):1863-1872. PMC
  30. Arnett DK, Blumenthal RS, Albert MA, et al. "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease." Journal of the American College of Cardiology. 2019;74(10):e177-e232. PMC
  31. Gallois Y, Vol S, Cacès E, Balkau B; D.E.S.I.R. Study Group. "Distribution of fasting serum insulin measured by enzyme immunoassay in an unselected population of 4,032 individuals. Reference values according to age and sex." Diabetes & Metabolism. 1996;22(6):427-431. PubMed
  32. Rohlfing C, Petroski G, Hatten-Beck M, et al. "The current status of serum insulin measurements and the need for standardization." Clinical Chemistry and Laboratory Medicine. 2025. PubMed
  33. Xu YY, Xu SM, Li XM, et al. "Validation of the ADVIA Centaur XP system for the determination of insulin and its application." Analytical Biochemistry. 2020;592:113582. PubMed
  34. Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. "Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study." Acta Diabetologica. 2015;52(5):905-915. PubMed
  35. Li S, Huang S, Mo ZN, et al. "Generating a reference interval for fasting serum insulin in healthy nondiabetic adult Chinese men." Singapore Medical Journal. 2012;53(12):821-825. PubMed
  36. Matli B, Schulz A, Koeck T, et al. "Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals." Clinical Chemistry and Laboratory Medicine. 2021;59(11):1844-1851. PubMed
  37. Marcovina S, Bowsher RR, Miller WG, et al. "Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup." Clinical Chemistry. 2007;53(4):711-716. PubMed
  38. Cohen RM, Franco RS, Khera PK, et al. "Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c." Blood. 2008;112(10):4284-4291. PubMed
  39. Rohlfing C, Hanson S, Weykamp C, et al. "Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods." Clinica Chimica Acta. 2016;455:80-83. PubMed
  40. Lacy ME, Wellenius GA, Sumner AE, et al. "Association of Sickle Cell Trait With Hemoglobin A1c in African Americans." JAMA. 2017;317(5):507-515. DOI
  41. English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. "The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review." Diabetologia. 2015;58(7):1409-1421. DOI
  42. Cavagnolli G, Pimentel AL, Freitas PA, Gross JL, Camargo JL. "Factors affecting A1C in non-diabetic individuals: Review and meta-analysis." Clinica Chimica Acta. 2015;445:107-114. PubMed
  43. Guo W, Zhou Q, Jia Y, Xu J. "Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review." Medical Science Monitor. 2019;25:8371-8378. PubMed
  44. Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L. "Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency." Journal of Internal Medicine. 1990;227(2):133-136. PubMed
  45. O'Keeffe DT, Maraka S, Rizza RA. "HbA1c in the Evaluation of Diabetes Mellitus." JAMA. 2016;315(6):605-606. DOI
  46. Kiniwa N, Okumiya T, Tokuhiro S, et al. "Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level." Scandinavian Journal of Clinical and Laboratory Investigation. 2019;79(6):377-380. PubMed
  47. Saudek CD, Derr RL, Kalyani RR. "Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c." JAMA. 2006;295(14):1688-1697. DOI
  48. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. "KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease." Kidney International. 2022;102(5S):S1-S127. DOI
  49. Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. "Glycemic Monitoring and Management in Advanced Chronic Kidney Disease." Endocrine Reviews. 2020;41(5):756-774. PubMed
  50. Stellingwerff T, Mountjoy M, McCluskey WT, et al. "Review of the scientific rationale, development and validation of the International Olympic Committee Relative Energy Deficiency in Sport Clinical Assessment Tool: V.2 (IOC REDs CAT2)." British Journal of Sports Medicine. 2023;57(17):1109-1118. PubMed
  51. Mountjoy M, Ackerman KE, Bailey DM, et al. "2023 International Olympic Committee's (IOC) consensus statement on Relative Energy Deficiency in Sport (REDs)." British Journal of Sports Medicine. 2023;57(17):1073-1097. PubMed
  52. Engdahl JH, Veldhuis JD, Farrell PA. "Altered pulsatile insulin secretion associated with endurance training." Journal of Applied Physiology. 1995;79(6):1977-1985. PubMed
  53. King DS, Dalsky GP, Staten MA, Clutter WE, Van Houten DR, Holloszy JO. "Insulin action and secretion in endurance-trained and untrained humans." Journal of Applied Physiology. 1987;63(6):2247-2252. PubMed
  54. Koehler K, Hoerner NR, Gibbs JC, Zinner C, Braun H, De Souza MJ, Schaenzer W. "Low energy availability in exercising men is associated with reduced leptin and insulin but not with changes in other metabolic hormones." Journal of Sports Sciences. 2016;34(20):1921-1929. PubMed
  55. Angelidi AM, Stefanakis K, Chou SH, Valenzuela-Vallejo L, Dipla K, Boutari C, Ntanasis-Stathopoulos I, Kokkoris P, Mantzoros CS. "Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments." Endocrine Reviews. 2024;45(5):676-708. PubMed
  56. Jørgensen SW, Hjort L, Gillberg L, et al. "Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males." American Journal of Physiology-Endocrinology and Metabolism. 2021;320(2):E281-E290. PubMed
  57. Stone SI, Balasubramanyam A, Posey JE. "Atypical Diabetes: What Have We Learned and What Does the Future Hold?" Diabetes Care. 2024;47(5):770-781. PMC
  58. Bojsen-Møller KN, Lundsgaard AM, Madsbad S, Kiens B, Holst JJ. "Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations-Role of Carbohydrate and Energy Availability." Diabetes. 2018;67(11):2129-2136. PubMed
Medical Disclaimer: This resource provides clinical context for educational purposes and is not medical advice. In Precision Medicine, the right metabolic strategy must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash or your own physician to interpret your metabolic labs, particularly if you have chronic health conditions or take prescription medications.

Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.

Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | About

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake

Frequently Asked Questions

Common Questions

Fishtown Medicine aims for a fasting insulin between 3 and 6 uIU/mL, sets 6.1 to 9.0 uIU/mL as borderline high, and treats 9.1 uIU/mL and above as high. Standard lab ranges often run up to 18 or 25 uIU/mL, which misses years of early insulin resistance.
Fishtown Medicine tests fasting insulin alongside HbA1c because the pancreas can keep blood sugar and HbA1c normal for years by secreting two to three times the normal amount of insulin. Measuring fasting insulin catches that metabolic strain early.
Fishtown Medicine keeps fasting insulin as a 3 to 6 uIU/mL range instead of "under 6" because levels of 1 or 2 uIU/mL frequently signal relative energy deficiency in sport (RED-S), where chronic under-fueling suppresses thyroid conversion, bone density, menstrual cycles in women, and testosterone in men.
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) combines fasting insulin and fasting glucose to estimate basal liver and peripheral insulin resistance. Classic HOMA1-IR equals (fasting insulin uIU/mL] x fasting glucose [mg/dL]) / 405 (where healthy cohorts center near ~1.0, IQR 0.85 to 1.42, and values above 2.0 signal significant resistance). HOMA2-IR uses a non-linear model with lower numerical cutoffs (95th percentile 1.80 vs 2.68 in Tohidi et al., 2014).[<sup>13</sup><sup>36</sup> Always compare the same formula on the same lab platform.
Yes. Even in healthy non-diabetic adults with normal blood counts, average red blood cell age varies from 38 to 60 days (Cohen et al., Blood 2008), which changes how long hemoglobin is exposed to sugar.<sup>38</sup> Iron deficiency and B12/folate deficiency often push HbA1c falsely higher, whereas hemolysis, advanced kidney disease, or sickle cell trait (-0.29 percentage points lower HbA1c at the same glucose, Lacy et al., JAMA 2017) push HbA1c falsely lower.<sup>40</sup><sup>41</sup><sup>46</sup>
A 2-to-4-week preventive CGM trial is very helpful when fasting insulin is above 6 uIU/mL, when TG/HDL-C exceeds 1.0 to 1.5, or when HbA1c and fasting glucose disagree. It shows which specific meals, late dinners, or short-sleep nights drive your personal glucose peaks without requiring lifelong continuous wear.

Deep-Dive Questions

In Whitehall II (Tabák et al., Lancet 2009, n = 6,538), adults who developed type 2 diabetes already had 34.2 percentage points lower HOMA2-%S insulin sensitivity and higher basal insulin secretion (85.0% vs 74.6%) 5 to 13 years before diagnosis. That was followed by steep beta-cell decompensation in the final 3 years (HOMA2-%B dropping to 62.4% as FPG rose from 104 to 133 mg/dL).<sup>1</sup> In IRAS (Festa et al., Diabetes 2006), repeat intravenous testing over 5.2 years proved that people kept normal glucose tolerance only by increasing acute insulin secretion +34% to offset a -35% drop in insulin sensitivity.<sup>6</sup> Because modeled FPG in Whitehall II was already ~98 mg/dL at -13 years, these studies prove early physiological compensation before diabetes diagnosis, while FPG and HbA1c remain the primary statistical predictors of crossing the glycemic line (Ruijgrok et al., Diabetologia 2018).<sup>1</sup><sup>3</sup>
The ADA/AACC laboratory guideline (Sacks et al., Diabetes Care 2023) highlights two key caveats: first, commercial insulin immunoassays are not standardized across manufacturers (12% to 66% inter-lab CV in Marcovina 2007; only 1 of 12 assays matched mass spectrometry in Rohlfing et al., CCLM 2025). Second, in population models that already include fasting glucose, HbA1c, lipids, and blood pressure (Hoorn, PROSPER), fasting insulin adds modest incremental discrimination for hard endpoints.<sup>3</sup><sup>25</sup><sup>26</sup><sup>32</sup> We address the assay limitation by tracking serial draws on the same laboratory platform and using insulin as a physiological lens alongside HbA1c, FPG, and ApoB instead of a standalone diagnostic test.
While a TG/HDL-C ratio (in mg/dL units) correlates with liver insulin resistance and predicts incident diabetes (Panasonic Cohort, Yuge 2023, n = 120,613) and heart events (HR 1.43, 1.26 after bias adjustment across 207,515 adults in Chen 2022), it frequently underestimates insulin resistance in adults of African ancestry (Kim-Dorner et al., Metabolism 2010), where triglyceride levels often stay normal despite marked insulin resistance.<sup>15</sup><sup>17</sup><sup>28</sup> Pairing fasting insulin/HOMA-IR with HbA1c and fasting glucose prevents missed cases.
Because HOMA-IR multiplies fasting insulin by fasting glucose, a patient with failing pancreatic beta cells (such as latent autoimmune diabetes in adults LADA], monogenic MODY, or pancreatic insufficiency) can have a fasting insulin of 1.5 uIU/mL and a fasting glucose of 128 mg/dL. That produces a seemingly "normal" HOMA1-IR of 0.47 (Stone et al., Diabetes Care 2024).[<sup>57</sup><sup>58</sup> Whenever low insulin appears alongside rising glucose or HbA1c, we evaluate insulin deficiency (C-peptide and islet autoantibodies) instead of celebrating high insulin sensitivity.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Metabolic Health

Metabolic Health

Why you feel tired at 3 PM, and how to fix it - insulin resistance, glucose swings, and the metabolic testing that catches dysfunction early.

Read Deep Dive
Your Relationship With Yourself: The Ground of Every Health Change | Fishtown Medicine

Your Relationship With Yourself: The Ground of Every Health Change | Fishtown Medicine

The relationships that shape your health reach beyond other people. The first one is with yourself: the story you tell, whether you choose yourself, and how you talk to yourself when it is hard. Why that relationship decides whether a health change sticks, from Fishtown Medicine in Philadelphia.

Read Deep Dive
Performance Physical Philadelphia: 4 Tests That Predict How You Age

Performance Physical Philadelphia: 4 Tests That Predict How You Age

A performance physical measures how well you are aging: VO2 max, grip strength, mobility, and body composition - the 4 tests that predict healthspan.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share where your weight and energy are now, what you have tried, and what you want the next year to look like. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs